Last reviewed · How we verify

NCT06641830

A Integrated Study in Pediatric Patients with Cardiomyopathy

ENROLLING BY INVITATION Last updated 15 October 2024
What this trial tests

trial in Pediatric Cardiomyopathy in 800 participants. Enrolling by invitation.

Timeline
1 September 2024
Primary endpoint
1 January 2034
30 September 2034

Quick facts

Lead sponsorWest China Second University Hospital
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment800
Start date1 September 2024
Primary completion1 January 2034
Estimated completion30 September 2034
Sites1 location across China

Conditions studied

Sponsor

West China Second University Hospital

Who can join

Under 18, any sex, with Pediatric Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study aims to manage children with cardiomyopathy in the long term. It collects baseline data, laboratory test data, and medical imaging data during the hospitalization and follow-up. During their disease progress, participants will undergo cardiovascular magnetic resonance, echocardiography, electrocardiography, laboratory tests, and when hospitalization and follow-up, and the baseline data will be collected in the admission. All the above examination data will be analysed to assess the clinical characteristics, current status of diagnosis and treatment, and the prognostic risk factors for children with cardiomyopathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other West China Second University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06641830.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing